Published on Nov 17, 2023 at 9:00 a.m.Updated Nov. 17, 2023 at 9:11 a.m.
This is a promising step forward to better combat sepsis. Toulouse biotech Abionyx Pharma (formerly Cerenis) obtained positive results in the phase II clinical trial of its recombinant good cholesterol (HDL) protein against a serious infection, sepsis. They were presented at the beginning of November on the BMC Medicine website of the scientific journal “Nature” and at the congress of the American Society of Nephrology, in Philadelphia.
Tested on 20 patients at the Bari hospital in Italy, its drug candidate CER-001, made up of apolipoprotein A1 (ApoA1), reduced the one-day mortality rate to 6.7%, compared to 20% in patients receiving standard treatment alone. And among seriously ill patients placed in intensive care, this rate rose to 14.7%, compared to 50% with standard treatment.